



Numerous animal experiments and clinical trials assessing the safety and feasibility of autologous progenitor cell transplantation have proven that cell-based strategy is very safe and effective. Cell therapy augments myocardial blood flow with associated alleviation of angina symptoms resulting in the patients' improved physical functioning. Recent studies also demonstrate that implantation of EPCs, cells which share many common characteristics with ACPs after Acute Myocardial Infarction appears to be safe and effective in limiting post-infarction damage. Thus, the potential benefit to patients is significant while the associated risk is minimal.

VesCell is a cellular-based product that has been proven effective for treating patients who suffer from Angina Pectoris. The cellular product has been applied in the processes of normal development, regeneration, damage repair, and proliferation of blood vessels. ACP therapy is ideal for heart patients who have exhausted other treatment options such as angioplasty (with or without stent implantation) or coronary artery bypass grafting (CABG) or for those who do not wish to undergo major surgery.

Since VesCell consists solely of autologous adult stem cells, the possibility of immunological incompatibility associated with allogenic cells does not exist. There is also no danger of cell contamination as there is absolutely no contact with animal-derived cells or materials at any time during VesCell manufacturing process. Unlike many other cell-harvesting strategies that require the painful harvesting of stem cells from bone marrow, VesCell's strategy relies solely upon the same simple and painless collection process used in everyday blood donations.